DEFENCE THERAPEUTICS A

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, DEFENCE THERAPEUTICS A had revenue of €0 and net profit of -€924.51k

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-22.92k	91.36%
Net profit	-924.51k	27.98%
EBITDA	-936.2k	34.34%

Fundamentals

Metric	Value
Market capitalization	€14.51m
Number of shares	76.11m
52-week high/low	€0.59 - €0.18
Dividends	No
Beta	1.51
P/E ratio	-2.72
PEG ratio	0.06
P/B ratio	6.48
P/S ratio	0.00

Company profile

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Name	DEFENCE THERAPEUTICS A
CEO	Amie Phinney
Headquarters	Montreal, qc Canada
Website	defencetherapeutics.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	18/05/2021
Employees	5